Pharmacologic class (EPC) · 6 drug pages

Dopamine-2 receptor antagonist: adverse event reports filed with FDA

40,014 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

40,014
reports across the class: 0.2% of all reports; 1,234
reports, 12 months to June 2026: 1,358 in the 12 months before; 91.9%
marked serious by the reporter: 57.4% across all reports; 6
drugs with a page: brand and generic names counted separately

Dopamine-2 receptor antagonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 6 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 40,014 adverse event reports received by FDA, 0.2% of the database, from January 2004 to June 2026.

1,234 reports arrived in the 12 months to June 2026, close to the 1,358 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 91.9% of the class's reports are marked serious, 7.1% record death among the outcomes and 23.6% record hospitalisation, as reported.

Across the class the reactions recorded most often are tardive dyskinesia (53.6%), extrapyramidal disorder (40.7%) and dystonia (23.7%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Metoclopramide	generic	22,305	595	96.4%	Tardive dyskinesia
ReglanMetoclopramide hydrochloride	brand	8,138	40	85.5%	Tardive dyskinesia
Metoclopramide hydrochloride	generic	4,550	112	86.4%	Tardive dyskinesia
Amisulpride	generic	3,503	295	98.4%	Drug ineffective
Droperidol	generic	990	111	91%	Anaphylactic shock
GimotiMetoclopramide hydrochloride	brand	528	81	5.5%	Dysgeusia

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Tardive dyskinesiainvoluntary repetitive movements53.6%21,444
Extrapyramidal disordermovement problems such as stiffness or tremor40.7%16,303
Dystoniainvoluntary muscle contractions23.7%9,480
Nervous system disorder19.7%7,879
Economic problema financial problem9.7%3,900
Incorrect drug administration duration9.7%3,882
Painpain, site not specified9.6%3,829
Dyskinesiainvoluntary movements9%3,608
Movement disorder8.5%3,419
Anxietyanxiety7.7%3,091
Activities of daily living impaired7.3%2,912
Tremorshaking6.8%2,716
Akathisiainner restlessness and an urge to move6.7%2,672
Deformity6%2,408
Multiple injuries5.6%2,234
Quality of life decreasedreduced quality of life5.1%2,044
Family stress4.8%1,929
Drug ineffectivethe medicine did not work as expected4.7%1,894
Emotional distressemotional distress4.5%1,815
Fear4.2%1,666
Drug interactionan interaction between medicines4%1,616
Anhedonia4%1,586
Nauseafeeling sick3.5%1,411
Off label useused for a purpose or in a way not on the label3.3%1,315
Unevaluable eventthe event could not be assessed3.2%1,278

Solid bar: share of all class reports. Hollow bar: the median share across the 6 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death7.1%2,858

Life-threatening3.9%1,576

Hospitalisation (initial or prolonged)23.6%9,444

Disability41.7%16,690

Congenital anomaly0.5%205

Other serious61.7%24,700

Not serious8.1%3,253

Patient age

Under 20.3%119

2 to 110.5%210

12 to 170.8%338

18 to 4412%4,813

45 to 649.8%3,920

65 to 744.2%1,673

75 and over3.2%1,295

Age not given69.1%27,646

Who reported

Physician12.4%4,953

Pharmacist3.5%1,389

Other health professional15.4%6,147

Lawyer55.3%22,126

Consumer or non-health professional10.5%4,199

Not given3%1,200

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Dopamine-2 receptor antagonist reports

Which drugs are in the Dopamine-2 receptor antagonist class on this site?

Metoclopramide, Reglan, Metoclopramide hydrochloride, Amisulpride, Droperidol and Gimoti. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

40,014 reports through June 2026, 1,234 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

tardive dyskinesia (53.6%), extrapyramidal disorder (40.7%), dystonia (23.7%), nervous system disorder (19.7%) and economic problem (9.7%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.